What is Foghorn Therapeutics Inc?
, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 103.14M, and a P/E ratio of 19.1x.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.